VKTX · Viking Therapeutics, Inc. · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| $509.32M | $344.96M | $101.64M | $63.81M | $54.23M | $44.98M | $31.93M | $23.56M | $19.04M | $13.74M | $9M | $6.97M | $22.22M | |
| $50.71M | $48.39M | $49.28M | $37.02M | $16.12M | $10.7M | $10.73M | $9.13M | $7.12M | $5.33M | $4.85M | $5.03M | $1.24M | |
| $560.02M | $393.34M | $150.92M | $100.83M | $70.36M | $55.68M | $42.66M | $32.69M | $26.16M | $19.07M | $13.85M | $12M | $23.47M | |
| -$560.02M | -$393.34M | -$150.92M | -$100.83M | -$70.36M | -$55.68M | -$42.66M | -$32.69M | -$26.16M | -$19.07M | -$13.85M | -$12M | -$23.47M | |
| $25.23M | $33.7M | $40.96M | $14.93M | $1.49M | $692K | $3.17M | $6.91M | $4.1M | -$1.51M | -$884.55K | -$11.41M | $1.58M | |
| — | -$359.64M | -$109.96M | -$85.9M | — | — | — | — | — | — | — | — | — | |
| — | $1000 | $1000 | $1000 | $1000 | $2000 | $0 | $0 | $0 | $0 | $0 | — | — | |
| -$534.8M | -$359.64M | -$109.96M | -$85.9M | -$68.87M | -$54.99M | -$39.5M | -$25.78M | -$22.06M | -$20.58M | -$14.73M | -$23.4M | -$21.88M | |
| -$535.78M | -$358.47M | -$110.36M | -$85.18M | -$69.42M | -$55.49M | -$39.56M | -$25.34M | -$22.47M | -$20.59M | -$14.73M | -$23.41M | -$21.88M | |
| USD/shares | -$4.67 | -$3.19 | -$1.01 | -$0.91 | -$0.90 | -$0.71 | — | — | — | — | — | — | — |
| USD/shares | -$4.67 | -$3.19 | -$1.01 | -$0.91 | -$0.90 | -$0.71 | — | — | — | — | — | — | — |
| shares | — | 112.67M | 109.04M | 94.35M | 76.83M | 77.2M | 72.6M | 71.96M | 57.58M | 25.98M | 16.28M | 6.36M | 4.19M |
| shares | — | 112.67M | 109.04M | 94.35M | 76.83M | 77.2M | 72.6M | 71.96M | 57.58M | 25.98M | 16.28M | 6.36M | 4.19M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2014–FY2022: $6.8M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 213 similar-size Biotechnology companies (of 537 listed).